HOUSTON, June 17, 2021 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers in the brain
and central nervous system, today announced that as part of the
annual reconstitution of the Russell stock indexes, CNS
Pharmaceuticals has been selected to be added to the Russell
2000® Index effective June 25,
2021, after the close of the U.S. equity markets.
John Climaco, CEO of CNS
Pharmaceuticals, commented "We are pleased to meet this noteworthy
milestone and be included in the Russell 2000® Index.
As our team continues to drive our clinical program forward for the
treatment of glioblastoma multiforme (GBM), we believe this
inclusion well-positions us to drive market awareness. We are
honored to be listed among our industry peers on what is considered
to be a widely respected performance benchmark for small-cap
companies. We look forward to leveraging the access and positioning
this inclusion brings to unlock additional value."
The Russell 2000® Index measures the performance of
the small-cap segment of the US equity market. The Russell
2000® Index is a subset of the Russell
3000® Index representing approximately 10% of the
total market capitalization of that index. It includes
approximately 2,000 of the smallest securities based on a
combination of their market cap and current index membership.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets are benchmarked against
Russell's U.S. indexes which are part of FTSE Russell, a global
index leader that provides innovative benchmarking, analytics and
data solutions for investors worldwide.
For more information on the Russell Indexes, please visit the
FTS Russell website at www.ftserussell.com.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its
WP1244 drug technology, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of WP1244 in the treatment of
brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
SOURCE CNS Pharmaceuticals, Inc.